(Hypertension. 1998;31:493.)
© 1998 American Heart Association, Inc.
Scientific Contributions |
From the Department of Geriatric Medicine, Osaka University Medical School, Suita, Japan (H.M., R.M., I.K., M.A., S.H., N.T., K.Y., A.M., J.H., T.O.), the Department of Radiation Biophysics, Kobe University, Kobe, Japan (A.N.), and the Institute for Cellular and Molecular Biology and Osaka University Medical School, Suita, Japan (Y.K.).
Correspondence to Toshio Ogihara, MD, PhD, Chief & Professor, Department of Geriatric Medicine, Osaka University Medical School, 2-2 Yamada-oka, Suita 565, Japan
| Abstract |
|---|
|
|
|---|
Key Words: gene therapy cell cycle regulatory gene bax bcl-2 remodeling
Abbreviations: DSF = defined serum-free medium HVJ = hemagglutinating virus of Japan sdi-1 = senescent cell-derived inhibitor-1 VSMC = vascular smooth muscle cells
| Introduction |
|---|
|
|
|---|
| Materials and Methods |
|---|
|
|
|---|
promoter was used in this study.16 This expression vector was derived from the plasmid pcDSR
296 vector (donated by Dr. Yoshida, University of Tokyo, Japan).28 The control vector that did not contain p21 gene was used as a control plasmid in this study.
Preparation of HVJ-Liposomes
The preparation of the HVJ-liposome complex has been described previously.10,11,29,30 Briefly, phosphatidylserine, phosphatidylcholine, and cholesterol were mixed in a weight ratio of 1:4.8:2. The lipid mixture (10 mg) was deposited on the sides of a flask by removal of tetrahydrofuran in a rotary evaporator. Dried lipid was hydrated in 200 µL BSS (in mmol/L: 137 NaCl, 5.4 KCl, 13 Tris-HCl, pH 7.6) containing DNA-high mobility group (HMG)-1 complex (200 µg:64 µg), which had previously been incubated at 20°C for 1 hour. Liposomes were prepared by shaking and sonicating. Purified HVJ (Z strain) was inactivated by UV irradiation (110 erg/mm2/sec) for 3 minutes just before use. The liposome suspension (0.5 mL, containing 10 mg lipid) was mixed with HVJ (35,000 hemagglutinating units) in a total volume of 2 mL BSS. The mixture was incubated at 4°C for 10 minutes and then for 30 minutes with gentle shaking at 37°C. Free HVJ was separated from the HVJ-liposome complex by sucrose density gradient centrifugation. The top layer of the sucrose gradient was collected for use. We have previously reported that this preparation method of HVJ-liposome complex for transfection of plasmid DNA into VSMC is highly efficient.30,31
Cell Culture
Human aortic VSMC (passage 5) were obtained from Clonetics Corp. (San Diego, CA) and cultured in modified MCDB131 medium supplemented with 5% fetal calf serum, 100 U/mL penicillin, 100 mg/mL streptomycin, 10 ng/mL epidermal growth factor, 2 ng/mL bovine fibroblast growth factor, and 1 mmol/L dexamethasone in the standard fashion. Cells were incubated at 37°C in a humidified atmosphere of 95% air/5% CO2 with changes of medium every 2 days. These cells showed the specific characteristics of VSMC, according to immunohistochemical examination and morphologic observation.32,33 Briefly, human aortic VSMC also tested positive for
-actin and negative for expression of factor VIII antigen. All the cells were used within passage 5 to 7.
In Vitro Transfection of p21 Vector
VSMC (1x106) were inoculated on day 0 and grown to 80% confluence in 5% calf serum. After 80% confluence was reached, the medium was changed to fresh defined serum-free medium (DSF) containing 2% serum. DSF medium was supplemented with insulin (5x10-7 mol/L), transferrin (5 mg/mL), and ascorbate (0.2 mmol/ L).34 Then, cells were washed three times with BSS containing 2 mmol/L CaCl2.30,31 HVJ-liposome complex (500 µL) containing 1.3 mg lipid and 2.5 µg encapsulated DNA and HMG-1 was added to the dishes. The cells were incubated at 4°C for 5 minutes and then at 37°C for 30 minutes. After incubation, the medium was changed to fresh medium containing 2% serum, and cells were incubated overnight in a CO2 incubator. The medium was again replaced with fresh medium containing 2% serum. Cell counting and staining for apoptosis were performed on day 4 after transfection.
Western Blotting
VSMC were seeded onto 10-cm dishes. VSMC were grown to confluence and made quiescent by incubation in DSF medium, before transfection. At 4 days after transfection into VSMC, the cells were collected by centrifugation after scraping, followed by extraction of total protein with lysis buffer (50 mmol/L Tris-HCl, pH 8.0, 20 mmol/L El)TA, 1% SDS, 100 mmol/L NaCl). Samples containing 50 µg protein were run on 12.5% SDS-polyacrylamide gels. Proteins were separated by SDS-PAGE, transferred to nitrocellulose membrane (Hybond ECL, Amersham, Buck-inghamshire, UK), and incubated with a monoclonal antibody to p21 (1:20, Calbiochem), bax (1:100; Santa Cruz Biotechnology, Inc., Santa Cruz, CA), or bcl-2 (1:50; Santa Cruz) at 4°C overnight. Antibodies were diluted in 4% skimmed milk and 0.1% Tween-20 in PBS. The membranes were then washed and incubated with a 1:2000 dilution of mouse or rabbit Ig horseradish peroxidase-conjugated antibody (Amersham). Bound antibodies were detected by enhanced chemiluminescence (ECL, Amersham) and Hyperfilm-MP (Amersham). To quantify and compare levels of proteins, the density of each band was measured by densitometry (Shimazu, Kyoto, Japan). Amounts of loaded proteins were equal confirmed by the staining with CBB (Sigma Chemical Co., St. Louis, MO). Staining with CBB revealed the identical protein amounts in all samples of Western blotting (data not shown).
Counting of Cell Number
VSMC were seeded onto uncoated 96-well tissue culture plates (Corning, Corning, NY). In the preparation of experiments for determination of cell count, the cells were grown to subconfluence. The cells were then incubated in DSF for 48 hours. After transfection, the medium was again changed to fresh DSF with 2% serum. Fresh medium with 2% serum was changed every 48 hours. On day 4, an index of cell proliferation was determined using sulfonated tetrazolium salt, 4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate (WST-1) cell counting kit which is similar to 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay (Wako, Osaka, Japan), because this compound produces a highly water-soluble formazan dye, which makes the assay procedure easier to perform.35 Tetrazolium salt has been used to develop a quantitative colorimetric assay for cell growth. The assay detects living, but not dead, cells. We confirmed that serum-stimulated increase in cell number was associated by increased absorbance at 450 nm (data not shown). Briefly, 50,000 cells/well reflects absorbance 1 in the manufactures recommended condition. The sensitivity of the WST assay is double that of the MTT assay. Under our experimental conditions, an increase in absorbance of 0.2 reflects an increase in cell number from 20,000 cells/well.
Counting of Apoptotic Cells
As an assay of cell death by apoptosis, we used fluorescent DNA-binding dyes to define nuclear chromatin morphologic features as a quantitative index of apoptosis within the cell culture system.3638 Cells to be analyzed for apoptosis were stained with Hoechst 33342 and viewed under fluorescence microscopy.3638 The use of membrane-permeable (H33342) dye allowed the determination of cell viability, plasma membrane integrity, and an accounting of any nonapoptotic toxic or necrotic death induced in the study groups. Cells were cultured in DSF medium for 2 days after reaching subconfluence. Transfection procedures were as described above. After staining with Hoechst 33342 (5 µg/mL in PBS), cells were counted under fluorescence microscopy.3638 Individual nuclei were visualized at x400 to distinguish the normal uniform nuclear pattern from the characteristic condensed coalesced chromatin pattern of apoptotic cells. Although chromatin undergoes condensation during mitosis, these cells can be readily distinguished from apoptotic cells by their uniform and equatorial pattern of chromatin condensation compared with the randomly coalesced pattern typical of apoptotic cells. To quantify apoptosis, 400 nuclei from random microscopic fields were analyzed by an observer blinded to the treatment groups. The total number of apoptotic cells in each section was summed and expressed as a percentage of the total cell number. At least 10 individual sections were evaluated per slide. Samples were coded so that the analysis was performed without knowledge of which treatment each individual cells had received. The reproducibility of the results was reported previously (intraobserver variability 2.4±0.3%, interobserver variability 3.4±0.5%).36 Photographs were obtained with a fluorescence microscope (x200, x400) (Olympus). The apoptotic index obtained is a cross-sectional and not a cumulative assessment at the time of harvest and may be an underestimate of the total apoptotic population, because apoptotic cells in prenuclear condensation phase would be scored as normal and because late-stage apoptotic cells whose cellular membranes have disintegrated may not be detected.
Also, we employed the measurement of cellular DNA fragmentation using cellular DNA fragmentation ELISA kit (Boehringer Mannheim, Germany), to quantify apoptosis.39 Cultured VSMC were incubated with 10 µmol/L BrdU overnight at 37°C in 5% CO2. At 4 days after transfection, lysing solution containing BSA, EDTA, and Tween-20 was added to each well. DNA fragments in 100 µL cell lysate supernatant were tested by ELISA. The supernatant was transferred to an anti-DNA-precoated microtiter plate and incubated for 60 minutes at 37°C. After washing, the samples were denatured and fixed by microwave irradiation for 5 minutes. After cooling the microtiter plate for 10 minutes at -20°C, anti-BrdU peroxidase-conjugated solution was added and the plate was incubated for 60 minutes at 37°C. Wells were again washed, TMB substrate solution was added, and the plate was incubated for 30 minutes at room temperature. Stopping solution (25 µL of 1 mol/L H2SO4) was then added to each well. Absorbance was measured at 450 nm (reference wavelength 690 nm). We confirmed that apoptosis by hypoxia is associated by decreased absorbance. Briefly, 10,000 apoptotic cells/ well reflects absorbance 1.5 in the manufacturers recommended condition. The sensitivity of DNA fragmentation ELISA assay is well correlated with the results from the conventional [3H]thymidine-based DNA fragmentation assay. Under our experimental conditions, an increase in absorbance of 0.2 reflects an increase in cell number from 2,000 apoptotic cells/well.
Statistical Analysis
All values are expressed as mean±SEM. ANOVA with subsequent Bonferronis test was used to determine the significance of differences in multiple comparisons. Values of P<.05 were considered statistically significant.
| Results |
|---|
|
|
|---|
30%, P<.01 versus vehicle, P<.05 versus control) as compared with that in VSMC transfected with control vector. There was no significant change in DNA fragmentation rate between untransfected VSMC and VSMC transfected with control vector.
|
|
|
|
Because bcl-2, an anti-apoptotic gene, and bax, a pro-apoptotic gene, are known to regulate apoptosis,40 levels of bcl-2 and bax were measured by Western blotting. As shown in Fig 5, bax protein was significantly increased in VSMC transfected with p21 gene as compared with control vector (P<.05). There was no significant difference in bax protein between untransfected VSMC and VSMC transfected with control vector. In contrast, as shown in Fig 6, transfection of p21 vector into VSMC did not alter bcl-2 protein as compared with control vector. Thus, the ratio of bax to bcl-2 was significantly increased in VSMC transfected with p21 vector as compared with untransfected VSMC and VSMC transfected with control vector (P<.05; Fig 7), possibly leading to apoptosis.
|
|
|
| Discussion |
|---|
|
|
|---|
cofactor PCNA.1618,22 Thus, researchers postulate that the p21 gene may be an ideal target for overexpression in the restenosis model as well as the vein graft model. Indeed, in a balloon injury model, in vivo transfection of p21 gene resulted in the inhibition of neointimal formation.19,20 On the other hand, a new concept has evolved that a fundamental pathologic feature of vascular disease is marked by the abnormal accumulation of cells within the intimal space, resulting in neointimal lesion formation produced by alterations in the homeostatic balance between cell growth and cell death.41,42 In particular, programmed cell death/apoptosis is not a rare phenomenon, and it also occurs in pathophysiologic conditions such as after vascular injury by either mechanical or biochemical means.43 Therefore, it is becoming increasingly apparent that many factors may influence apoptosis in vascular cells. Among the many genes that have been suggested to be required by the molecular mechanism dictating apoptotic death, some have been shown to function as pacemakers to pave the way for cells either to live or to die. Probably, expressions of immediate early genes associated with the G1 phase of the cell cycle are candidates for this function. As reported previously, a well-known key regulator for halting the cell cycle at the G1/S interphase, p21, is involved in the execution of suicidal cell death in quiescent mouse 3T3 fibroblasts.23 However, postulated roles for p21 in apoptosis remain controversial, because both induction and protection from apoptosis were reported previously.2325 Moreover, none of the reports mentioned the induction of apoptosis by p21 in VSMC. We therefore tested the hypothesis that overexpression of p21 gene would result in the inhibition of VSMC through the induction of apoptosis. Inhibition of human aortic VSMC by p21 overexpression was accompanied by the induction of apoptosis in human VSMC. This is the first study to demonstrate induction of apoptosis mediated by p21 in human VSMC. The number of apoptotic cells was relatively low, although transfection efficiency of HVJ-liposome method into VSMC is approximately 8090% (unpublished observation; 31). Overexpression of p21 gene may not induce apoptosis in all cells, which is different from the inhibition of cell cycle progression. Probably, cells may undergo apoptosis only in certain conditions, such as inappropriate cell cycle progression. To elucidate the molecular mechanisms of induction of apoptosis by p21, we measured bcl-2 and bax proteins. Bcl-2 and bax are homologous proteins that have opposing effects on cell life and death, with bcl-2 serving to prolong cell survival and bax acting as an accelerator of apoptosis.44,45 The bcl-2 and bax proteins can form heterodimers in cells.40 Our data revealed the inappropriate induction of bax to bcl-2, because overexpression of p21 resulted in a significant increase in bax protein and no change in bcl-2 protein. In the present study, we showed that upregulation of p21 is functionally related to the operational efficiency of the apoptotic process in human aortic VSMC transfected with p21 vector to increase the endogenous p21 protein level, although the susceptibility to apoptosis may be different among species of VSMC (p53-sensitive human and rabbit VSMC, and p53-resistant rat VSMC).46 An additional increase of p21 beyond the base level, seen in serum-stimulated human VSMC, may be involved in the molecular events precipitating a rapid program of cell demise. Although there is no apparent evidence of induction of apoptosis by overexpression of p21 in vivo, the present results suggest that induction of apoptosis through bax pathway may at least participate in the inhibition of VSMC in vitro. Apoptosis occurs within the context of restenosis after angioplasty in human subjects and experimental animals.4143 Yang et al reported induction of endogenous p21 in balloon-injured porcine arteries;20 therefore, induction of p21 in vessels may contribute to cell death by apoptosis.
On the other hand, the induction of p21 has been reported to be coupled to the expression of early differentiation markers in myoblasts.24 Induction of cdk inhibitors may serve to maintain differentiated myocytes. It is recognized that VSMC involved in neointimal hyperplasia undergo a phenotypic change from a contractile to a secretory state, and these "activated" neointimal VSMC may release numerous cytokines that could, in turn, influence endothelial function and stimulate atherogenesis. Therefore, redifferentiation from neonatal to adult VSMC may have therapeutic value in inhibition of neointimal formation. As reported previously,21 overexpression of p21 gene in a vein graft model induced expression of the adult phenotype of VSMC in the formed neointima, which is less "synthetic" and closer to normal vascular structure. In addition to the inhibition of cell growth accompanied by apoptosis, the reexpressed adult-type phenotype might contribute to the inhibition of neointimal hyperplasia. Overall, these results demonstrated that inhibition of VSMC growth by overexpression of human p21 gene was accompanied by induction of apoptosis through an inappropriate increase in bax protein, which suggests that regulation of the cell cycle may be closely linked to apoptosis in human VSMC.
| Acknowledgments |
|---|
Received September 16, 1997; first decision October 24, 1997; accepted October 31, 1997.
| References |
|---|
|
|
|---|
2. Clowes AW, Clowes MM, Fingerle J, Reidy MA. Regulation of smooth muscle cell growth in injured artery. J Cardiovasc Pharmacol. 1989; 14 : S12 S15.
3. Lindner V, Reidy MA. Proliferation of smooth muscle cells after vascular injury is inhibited by an antibody against basic fibroblast growth factor.
Proc Natl Acad Sci U S A. 1991;
88
: 3739
3743.
4. Ferns GAA, Raines EW, Sprugel KH, Motani AS, Reidy MA, Ross R. Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF.
Science. 1991;
253
: 1129
1132.
5. Majesky MW, Lindner V, Twardzik DR, Schwartz SM, Reidy MA. Production of transforming growth factor beta-1 during repair of arterial injury. J Clin Invest. 1991; 88 : 904 910.[Medline] [Order article via Infotrieve]
6. Pagano M, Pepperkok R, Verde F, Ansorge W, Draetta G. Cyclin A is required at two points in the human cell cycle. EMBO J. 1992; 11 : 961 971.[Medline] [Order article via Infotrieve]
7. Pardee AB. A restriction point for control of normal animal cell proliferation.
Proc Natl Acad Sci U S A. 1974;
71
: 1286
1290.
8. Weintraub SJ, Prater CA, Dean DC. Retinoblastoma protein switches the E2F site from positive to negative element. Nature. 1992; 358 : 259 261.[Medline] [Order article via Infotrieve]
9. Pagano M, Draetta G, Durr J. Association of cdk 2 kinase with the transcription factor E2F during S phase.
Science. 1992;
255
: 1144
1147.
10. Morishita R, Gibbons GH, Ellison KE, Nakajima M, Zhang L, Kaneda Y, Ogihara T, Dzau VJ. Single intraluminal delivery of antisense cdc 2 kinase and PCNA oligonucleotides results in chronic inhibition of neointimal hyperplasia.
Proc Natl Acad Sci U S A. 1993;
90
: 8474
8478.
11. Morishita R, Gibbons GH, Ellison KE, Nakajima M, Leyen HVL, Zhang L, Kaneda Y, Ogihara T, Dzau VJ. Intimal hyperplasia after vascular injury is inhibited by antisense cdk 2 kinase oligonucleotides. J Clin Invest. 1994; 93 : 1458 1464.[Medline] [Order article via Infotrieve]
12. Chang MW, Barr E, Seltzer J, Jiang YQ, Nabel GJ, Nabel EG, Parmacek MS, Leiden JM. Cytostatic gene therapy for vascular proliferative disorder with a constitutively active form of the retinoblastoma gene product.
Science. 1995;
267
: 518
522.
13. Simons M, Edelman ER, Rosenberg RD. Antisense proliferating cell nuclear antigen oligonucleotides inhibit intimal hyperplasia in a rat carotid artery injury model. J Clin Invest. 1994; 93 : 2351 .[Medline] [Order article via Infotrieve]
14. Vogelstein B, Kinzler KW. P53 function and dysfunction. Cell. 1992; 70 : 523 526.[Medline] [Order article via Infotrieve]
15. Lane DP. p53, guardian of the genome. Nature. 1992; 258 : 15 16.
16. Noda A, Ning Y, Venable SF, Pereira-Smith OM, Smith JR. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp Cell Res. 1994; 211 : 90 98.[Medline] [Order article via Infotrieve]
17. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzeler KW, Vogelstein B. WAF 1, a potential mediator of p53 tumor suppression. Cell. 1993; 75 : 817 825.[Medline] [Order article via Infotrieve]
18. Harper JW, Adami GR, Wei N, Keyomarski K, Elledge SJ. The p21 CDK-interacting protein Cip 1 is a potential inhibitor of G1 cyclin-dependent kinases. Cell. 1993; 75 : 805 816.[Medline] [Order article via Infotrieve]
19. Chang MW, Barr E, Liu MM, Barton K, Leiden JM. Adenovirus-mediated over-expression of the cyclin/cyclin-dependent kinase inhibitor, p21 inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty. J Clin Invest. 1995; 96 : 2260 2268.[Medline] [Order article via Infotrieve]
20. Yang ZY, Simari RD, Perkins ND, San H, Gordon D, Nabel GJ, Nabel EG. Role of the p21 cyclin-dependent kinase inhibitor in limiting intimal cell proliferation in response to arterial injury.
Proc Natl Acad Sci U S A. 1996;
93
: 7905
7910.
21. Bai HZ, Sawa Y, Yamanaka T, Zhang WD, Morishita R, Matsuda J, Matsuda H. Gene transfer of senescent cell-derived inhibitor 1 into vein graft inhibited neointimal hyperplasia in vivo associated with induction of smooth muscle cell redifferentiation. Circulation. 1995; 92 : I-295 . Abstract.
22. Waga S, Hannon GJ, Beach D, Stillman B. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature. 1994; 369 : 574 578.[Medline] [Order article via Infotrieve]
23. Duttaroy A, Qian JF, Smith JS, Wang E. Up-regulated P21CIP1 expression is part of the regulation quantitatively controlling serum deprivation-induced apoptosis. J Cell Biochem. 1997; 64 : 434 446.[Medline] [Order article via Infotrieve]
24. Wang J, Walsh K. Resistance to apoptosis conferred by Cdk inhibitors during myocyte differentiation. Science. 1996; 273 : 359 361.[Abstract]
25. Steinman RA, Hoffman B, Iro A, Guillouf C, Liebermann DA, el-Houseini ME. Induction of p21 (WAF-1/CIP1) during differentiation. Oncogene. 1994; 9 : 3389 3396.[Medline] [Order article via Infotrieve]
26. Jiang H, Lin J, Su ZZ, Collart FR, Huberman E, Fisher PB. Induction of differentiation in human promyelocytic HL-60 leukemia cells activates p21, WAF1/CIP1, expression in the absence of p53. Oncogene. 1994; 9 : 3397 3406.[Medline] [Order article via Infotrieve]
27. Moretti F, Farsetti A, Soddu S, Misiti S, Crescenzi M, Filetti S, Andreoli M, Sacchi A, Pontecorvi A. p53 re-expression inhibits proliferation and restores differentiation of human thyroid anaplastic carcinoma cells. Oncogene. 1997; 14 : 729 740.[Medline] [Order article via Infotrieve]
28. Takebe Y, Seiki M, Fujisawa J, Hoy P, Yokota K, Arai K, Yoshida M, Arai N. SR alpha promoter: an efficient and versatile mammalian cDNA expression system composed of the simian virus 40 early promoter and the R-U5 segment of human T-cell leukemia virus type 1 long terminal repeat.
Mol Cell Biol. 1988;
8
: 466
472.
29. Kaneda Y, Iwai K, Uchida T. Increased expression of DNA cointroduced with nuclear protein in adult rat liver.
Science. 1989;
243
: 375
378.
30. Morishita R, Gibbons GH, Ellison KE, Lee W, Zhang L, Kaneda Y, Ogihara T, Dzau VJ. Evidence for direct local effect of angiotensin in vascular hypertrophy: in vivo gene transfer of angiotensin converting enzyme. J Clin Invest. 1994; 94 : 978 984.[Medline] [Order article via Infotrieve]
31. Yonemitsu Y, Kaneda Y, Morishita R, Nakagawa K, Nakashima Y, Sueishi K. Characterization of in vivo gene transfer into the arterial wall mediated by the Sendai virus (hemagglutinating virus of Japan) liposomes: an effective tool for the in vivo study of arterial diseases. Lab Invest. 1996; 75 : 313 323.[Medline] [Order article via Infotrieve]
32. Bonin PD, Leadley RJ, Erickson LA. Growth factor-induced modulation of endothelial-1 binding to human smooth muscle cells. J Cardiovasc Pharmacol. 1993; 22 : S125 S127.[Medline] [Order article via Infotrieve]
33. Morishita R, Nakamura S, Nakamura Y, Aoki M, Moriguchi A, Kida I, Yo Y, Matsumoto K, Nakamura T, Higaki J, Ogihara T. Potential role of endothelium-specific growth factor, hepatocyte growth factor, on endothelial damage in diabetes mellitus. Diabetes. 1997; 46 : 138 142.[Abstract]
34. Libby P, OBrien KV. Culture of quiescent arterial smooth muscle cells in a defined serum-free medium. J Cell Physiol. 1983; 115 : 217 223.[Medline] [Order article via Infotrieve]
35. Ishiyama M, Shiga M, Sasamoto K, Mizoguchi M, He P. A new sulfonated tetrazolium salt that produces a highly water-soluble formazan dye. Chem Pharm Bull. 1993; 41 : 1118 1122.
36. Bennett MR, Schwartz SM. Apoptosis of human vascular smooth muscle cells derived from normal vessels and coronary atherosclerotic plaques. J Clin Invest. 1995; 95 : 2266 2274.[Medline] [Order article via Infotrieve]
37. Pollman MJ, Yamada T, Horiuchi M, Gibbons GH. Vasoactive substances regulate vascular smooth muscle cell apoptosis: countervailing influences of nitric oxide and angiotensin II.
Circ Res. 1996;
79
: 748
756.
38. Aoki M, Morishita R, Matsushita H, Nakano N, Hayashi S, Tomita N, Yamamoto K, Moriguchi A, Higaki J, Ogihara T. Serum deprivation induced apoptosis accompanied by up-regulation of p53 and bax in human aortic vascular smooth muscle cells. Heart Vessels. 1997; 12 (suppl): 71 75.[Medline] [Order article via Infotrieve]
39. Oberhammer FA, Pavelka M, Sharma S, Tiefenbacher R, Purchio AF, Bursch W, Shulte-Hermann R. Induction of apoptosis in cultured hepatocytes and in regressing liver by transforming growth factor ß1.
Proc Natl Acad Sci U S A. 1992;
89
: 5408
5412.
40. Reed JC. Bcl-2 and the regulation of programmed cell death.
J Cell Biol. 1994;
124
: 1
6.
41. Isner JM, Kearney M, Bortman S, Passeri J. Apoptosis in human atherosclerosis and restenosis.
Circulation. 1995;
91
: 2703
2711.
42. Cho A, Courtman DW, Langille BL. Apoptosis (programmed cell death) in arteries of the neonatal lamb.
Circ Res. 1995;
76
: 168
175.
43. Han DKM, Haudenschild CC, Hong MK, Tinkle BT, Leon MB, Liau G. Evidence for apoptosis in human atherogenesis and in a rat vascular injury model. Am J Pathol. 1995; 147 : 267 277.[Abstract]
44. Selvakumaran M, Lin HK, Miyashita T, Wang HG, Krajewski S, Reed JC, Hoffman B, Liebermann D. Immediate early up-regulation of bax expression by p53 but not TGF ß1: a paradigm for distinct apoptotic pathways. Oncogene. 1994; 9 : 1791 1798.[Medline] [Order article via Infotrieve]
45. Sato T, Hanada M, Bodrugh S, Irie S, Iwama N, Boise L, Thompson C, Golemis E, Fong L, Wang HG, Reed JC. Interactions among members of the bcl-2 protein family analyzed with a yeast two-hybrid system.
Proc Natl Acad Sci U S A. 1994;
91
: 9238
9242.
46. Johnson TM, Epstein SE, Finkel T. Species-specific induction of apoptosis in normal vascular smooth muscle cells using an adenoviral expressing human p53. Circulation. 1996; 94 : I-155 . Abstract.
This article has been cited by other articles:
![]() |
T. S. Udayakumar, P. Hachem, M. M. Ahmed, S. Agrawal, and A. Pollack Antisense MDM2 Enhances E2F1-Induced Apoptosis and the Combination Sensitizes Androgen-Dependent and Androgen-Independent Prostate Cancer Cells to Radiation Mol. Cancer Res., November 1, 2008; 6(11): 1742 - 1754. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. A. Hruska, S. Mathew, and G. Saab Bone Morphogenetic Proteins in Vascular Calcification Circ. Res., July 22, 2005; 97(2): 105 - 114. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Chandiwal, V. Balasubramanian, Z. K. Baldwin, M. S. Conte, and L. B. Schwartz Gene Therapy for the Extension of Vein Graft Patency: A Review Vascular and Endovascular Surgery, January 1, 2005; 39(1): 1 - 14. [Abstract] [PDF] |
||||
![]() |
E. R. Vickers, A. Kasza, I. A. Kurnaz, A. Seifert, L. A. H. Zeef, A. O'Donnell, A. Hayes, and A. D. Sharrocks Ternary Complex Factor-Serum Response Factor Complex-Regulated Gene Activity Is Required for Cellular Proliferation and Inhibition of Apoptotic Cell Death Mol. Cell. Biol., December 1, 2004; 24(23): 10340 - 10351. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Lin, X. Zhu, F. L. Mclntee, H. Xiao, J. Zhang, M. Fu, and Y. E. Chen Interferon Regulatory Factor-1 Mediates PPAR{gamma}-Induced Apoptosis in Vascular Smooth Muscle Cells Arterioscler Thromb Vasc Biol, February 1, 2004; 24(2): 257 - 263. [Abstract] [Full Text] |
||||
![]() |
B. B. Davis, Y. Dong, and R. H. Weiss Overexpression of p73 causes apoptosis in vascular smooth muscle cells Am J Physiol Cell Physiol, January 1, 2003; 284(1): C16 - C23. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Nonomura, H. Kohsaka, K. Nasu, Y. Terada, M.-a. Ikeda, and N. Miyasaka Suppression of arthritis by forced expression of cyclin-dependent kinase inhibitor p21Cip1 gene into the joints Int. Immunol., June 1, 2001; 13(6): 723 - 731. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Kawauchi, J.-i. Suzuki, R. Morishita, Y. Wada, A. Izawa, N. Tomita, J. Amano, Y. Kaneda, T. Ogihara, S. Takamoto, et al. Gene Therapy for Attenuating Cardiac Allograft Arteriopathy Using Ex Vivo E2F Decoy Transfection by HVJ-AVE-Liposome Method in Mice and Nonhuman Primates Circ. Res., November 24, 2000; 87(11): 1063 - 1068. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. H. Weiss, A. Joo, and C. Randour p21Waf1/Cip1 Is an Assembly Factor Required for Platelet-derived Growth Factor-induced Vascular Smooth Muscle Cell Proliferation J. Biol. Chem., March 31, 2000; 275(14): 10285 - 10290. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-i. Hayashi, R. Morishita, H. Matsushita, H. Nakagami, Y. Taniyama, T. Nakamura, M. Aoki, K. Yamamoto, J. Higaki, and T. Ogihara Cyclic AMP Inhibited Proliferation of Human Aortic Vascular Smooth Muscle Cells, Accompanied by Induction of p53 and p21 Hypertension, January 1, 2000; 35(1): 237 - 243. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-P. Tsao, S.-J. Huang, J.-L. Chang, J.-T. Hsieh, R.-C. Pong, and S.-L. Chen Adenovirus-Mediated p21(WAF1/SDII/CIP1) Gene Transfer Induces Apoptosis of Human Cervical Cancer Cell Lines J. Virol., June 1, 1999; 73(6): 4983 - 4990. [Abstract] [Full Text] |
||||
![]() |
J.-M. Li and G. Brooks Cell cycle regulatory molecules (cyclins, cyclin-dependent kinases and cyclin-dependent kinase inhibitors) and the cardiovascular system; potential targets for therapy? Eur. Heart J., March 2, 1999; 20(6): 406 - 420. [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1998 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |